Angela Rago

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 67 publications

Pregnancy after breast cancer: obstetrics and feto-maternal outcomes.

Pregnancy after breast cancer: obstetrics and feto-maternal outcomes.

Journal: European review for medical and pharmacological sciences

Published: September 01, 2026

Correction: Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional network.

Correction: Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional network.

Journal: Frontiers in oncology

Published: February 16, 2026

Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional network.

Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional network.

Journal: Frontiers in oncology

Published: December 07, 2025

A nationwide Italian GIMEMA survey on tandem autologous stem cell transplantation for newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, thalidomide and dexamethasone.

A nationwide Italian GIMEMA survey on tandem autologous stem cell transplantation for newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, thalidomide and dexamethasone.

Journal: Haematologica

Published: November 17, 2025

MRD in multiple myeloma: the clinical perspective.

MRD in multiple myeloma: the clinical perspective.

Journal: Frontiers in oncology

Published: November 05, 2025

The Strange Case of Functional High-Risk Multiple Myeloma Patients: Is It Possible to Identify Them in Clinical Practice?

The Strange Case of Functional High-Risk Multiple Myeloma Patients: Is It Possible to Identify Them in Clinical Practice?

Journal: Cancers

Published: October 08, 2025

Imaging in Plasma-Cell Neoplasms: Italian Experts' Recommendations.

Imaging in Plasma-Cell Neoplasms: Italian Experts' Recommendations.

Journal: European journal of haematology

Published: September 27, 2025

HBV infection in the era of T-cell engagers in multiple myeloma: unresolved challenges and unmet needs. Comment on: "Hepatitis B virus reactivation following T-cell engager therapy in multiple myeloma despite negative hepatitis B core antibody serology: implications for screening in patients with hematological malignancies".

HBV infection in the era of T-cell engagers in multiple myeloma: unresolved challenges and unmet needs. Comment on: "Hepatitis B virus reactivation following T-cell engager therapy in multiple myeloma despite negative hepatitis B core antibody serology: implications for screening in patients with hematological malignancies".

Journal: Haematologica

Published: August 14, 2025

Cytogenetic Features and Their Implications in Clinical Practice: A Real-World Analysis of a Large Cohort of Multiple Myeloma Patients.

Cytogenetic Features and Their Implications in Clinical Practice: A Real-World Analysis of a Large Cohort of Multiple Myeloma Patients.

Journal: Clinical lymphoma, myeloma & leukemia

Published: July 13, 2025

Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape.

Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape.

Journal: ESMO open

Published: July 11, 2025

Infection events in patients with newly diagnosed multiple myeloma with anti-CD38 monoclonal antibody-based first line regimens: A multicentric Italian experience.

Infection events in patients with newly diagnosed multiple myeloma with anti-CD38 monoclonal antibody-based first line regimens: A multicentric Italian experience.

Journal: Annals of hematology

Published: May 29, 2025

Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 Patients.

Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 Patients.

Journal: European journal of haematology

Published: January 31, 2025

Showing 1-12 of 67

Last Updated: 09/26/2026